QuaCell^™ CHO-K1Q: Supporting the Journey from Discovery to Preclinical Development

🧬 From Cell Line to Candidate Molecule

Fresh from the pages of Science, a 2026 publication details the development of hu-IB101—a humanized covalent PD-L1 antagonist advanced into preclinical evaluation, including PK/PD and safety studies in cynomolgus monkeys.

In the CRO/CDMO world, “good enough” expression isn’t enough. You need platforms that deliver both discovery agility and regulatory rigor.

That’s why the QuaCell^™ CHO-K1Q cell line was selected for this program. It provided the robust, scalable expression required to move from benchtop discovery to GLP-grade material for monkey studies.

For biologics developers, the cell line is more than an expression host—it is the foundation connecting scientific breakthroughs to viable candidate molecules.

We are proud to see our cell culture platform supporting programs that progress beyond early research and into the clinic. From cell line development to media optimization, LePure Biotech remains committed to enabling the next generation of biologics.